A patent need to look at ethics
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.From Mr Steve Emmott
Sir: Your two patent lawyer correspondents (Letters, 4 March), writing in response to the news that the European Parliament has rejected the EU directive on patenting life forms, both seek to portray the decision as being of little consequence for the biotechnology industry. This is curiously at odds with the furious lobbying that was going on in Brussels up to the last moment and the appearance of industry representatives on TV and radio arguing that rejection would sound the death knell for future investment in Europe.
There is no doubt that deep issues are raised by the creation of new genetically engineered plants and animals and the possibility of genetic manipulation of living human material. One MEP put his finger directly on the problem when he said in the debate that, until we got a satisfactory consensus of opinion on the ethics of biotechnology, it was simply inappropriate to grant private commercial monopolies on genetic material.
What we need is a cool look at what is, and what is not, acceptable to society in the use of this technology. Our MEPs have created the opportunity for this to happen. If industry presses on regardless with ad hoc patent applications, it will run into the same determined opposition that blocked the directive.
Yours faithfully,
STEVE EMMOTT
Patent Concern Coalition
The Genetics Forum
London, EC2
4 March
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments